NCT04638725View on ClinicalTrials.gov

Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer

RecruitingOBSERVATIONAL
Enrollment

9,000

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

December 15, 2029

Study Completion Date

December 15, 2029

Conditions
HER2-positive Breast Cancer
Interventions
OTHER

Blood sample for genetic analysis

Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study

Trial Locations (1)

67033

RECRUITING

Institut de cancérologie Strasbourg Europe, Strasbourg

All Listed Sponsors
lead

Institut de cancérologie Strasbourg Europe

OTHER